RECIST
Showing 1 - 25 of >10,000
Follow up After TACE by Elastography and Color Doppler.
Not yet recruiting
- Hepatocellular Carcinoma
- US
- (no location specified)
Oct 2, 2023
Efficacy of Targeted Therapy for NSCLC
Recruiting
- Evaluation
- +2 more
- RecistTM criteria
-
Chongqing, Chongqing, ChinaCancer Center, Dapping Hospital, Army Medical Center of PLA
Nov 15, 2023
NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor Trial in Boulogne
Recruiting
- NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor
- assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
-
Boulogne Billancourt, France
- +2 more
Jul 12, 2021
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 Trial in
Recruiting
- Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
- Biological : Toripalimab Drug: Axitinib
- sunitinib
-
Beijing, ChinaBeijing Cancer Hospital
Jan 24, 2021
Pancreatic Neuroendocrine Tumors: Comparison Between Choi and
Completed
- Pancreatic Neuroendocrine Tumors
-
Santander, Cantabria, Spain
- +9 more
Mar 23, 2020
Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1
Completed
- Poorly Differentiated Malignant Neuroendocrine Carcinoma
- +4 more
- Everolimus (Afinitor®)
-
Berlin, GermanyCharité-Universitätsmedizin, Medizinische Klinik m. S. Hepatolog
Oct 27, 2020
Non Small Cell Lung Cancer Trial in Detroit (drug, diagnostic test, other)
Unknown status
- Non Small Cell Lung Cancer
- Nivolumab
- +2 more
-
Detroit, MichiganHenry Ford Health Systems
Mar 25, 2020
Endometrial Cancer Trial (MK-2870, Doxorubicin, Paclitaxel)
Not yet recruiting
- Endometrial Cancer
- MK-2870
- +2 more
- (no location specified)
Nov 10, 2023
Relapsed/Refractory Small Cell Lung Cancer Trial in Worldwide (Tarlatamab)
Recruiting
- Relapsed/Refractory Small Cell Lung Cancer
-
Birmingham, Alabama
- +78 more
Jan 18, 2023
Fibrolamellar Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, DRP-104)
Not yet recruiting
- Fibrolamellar Hepatocellular Carcinoma
-
Baltimore, MarylandJohns Hopkins SKCCC
Aug 30, 2023
Colorectal Cancer Trial in Shanghai (FOLFIRI+Bevacizumab)
Recruiting
- Colorectal Cancer
-
Shanghai, Pudong, ChinaAffiliated Cancer Hospital of Fudan University
Jul 24, 2023
Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)
Recruiting
- Advanced Solid Tumors
- Metastatic Solid Tumors
-
Lyon, FranceCentre Léon Bérard
Nov 30, 2022
Squamous Cell Carcinoma Trial (MK-3475A)
Not yet recruiting
- Squamous Cell Carcinoma
- MK-3475A
- (no location specified)
Sep 11, 2023
Therapy Using 18F-FSPG PET
Not yet recruiting
- Cancer
- +3 more
- 18F-FSPG PET/CT in NSCLC
- 18F-FSPG PET/CT in HNSCC
- (no location specified)
May 24, 2023
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy
Not yet recruiting
- Non-small Cell Lung Cancer Metastatic
- (no location specified)
Sep 13, 2023
Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)
Not yet recruiting
- Recurrent Ovarian Cancer
- Fuzuloparib Combination with Bevacizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Cente
Apr 14, 2023
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)
Not yet recruiting
- Solid Tumor
- +2 more
- favezelimab/pembrolizumab
- +2 more
- (no location specified)
Sep 7, 2023
Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody
Recruiting
- Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
- AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
-
Shanghai, Shanghai, ChinaShanghai Renji Hospital
Sep 12, 2023
Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Worldwide (biological, drug, other)
Recruiting
- Ovarian Cancer
- +2 more
- Pembrolizumab
- +4 more
-
Phoenix, Arizona
- +178 more
Jan 25, 2023
Colorectal Cancer Trial in China (TQB2618 injection, Penpulimab injection, Anlotinib HCl capsules)
Not yet recruiting
- Colorectal Cancer
- TQB2618 injection
- +2 more
-
Fuyang, Anhui, China
- +14 more
Aug 23, 2023
Squamous Cell Carcinoma of Head and Neck Trial in France, Spain, United States (Setanaxib, Pembrolizumab, Placebo)
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- Setanaxib
- +2 more
-
Miami Beach, Florida
- +28 more
Jan 19, 2023
